RNAM
Avidity Biosciences trades as RNAM and has a market capitalization of $11.25 B, making it the #885 largest US-listed company by market value. This page tracks Avidity Biosciences through 0 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
2026-05-29
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
2026 MDA Clinical & Scientific Congress Presentations
Avidity intends to adjourn the Special Meeting to provide additional time to satisfy the conditions to the pro rata distribution of all of the issued and outstanding shares of Atrium Therapeutics, Inc. ("SpinCo") common stock to Avidity's stockholders (the "Distribution"). The Distribution is a condition to the closing of Avidity's previously announced proposed merger with Novartis AG (the "Merger").
Del-desiran effectively delivered siRNA to muscle, resulting in approximately 40% mean reduction in DMPK mRNA and amelioration of missplicing
Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare muscle diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly owned precision cardiology development candidates addressing rare genetic cardiomyopathies. In addition, Avidity is broadening the reach of AOCs with its advancing and expanding pipeline
"We recognize the considerable needs facing the DMD44 community given there are no approved exon skipping therapies for this disease as well as the potential of del-zota based on the unprecedented data shown in our clinical studies," said Sarah Boyce , President and Chief Executive Officer of Avidity. "We are pleased to open this MAP to enable a compliant approach to providing del-zota to eligible patients as quickly as possible."
Avidity Biosciences (RNAM) has a market capitalization of $11.25 B as of 2026-05-29, ranking #885 among US-listed companies.